OXFORD BIODYNAMICS PLC
Develops precision blood tests using 3D genomics for cancer diagnosis and therapy guidance.
OBD | IL
Overview
Corporate Details
- ISIN(s):
- GB00BD5H8572 (+2 more)
- LEI:
- 2138005Y1TK258O5U928
- Country:
- United Kingdom
- Address:
- 3140 ROWAN PLACE, JOHN SMITH DRIVE, OX4 2WB OXFORD
- Sector:
- Professional, scientific and technical activities
- Industry:
- Research and experimental development on natural sciences and engineering
Description
Oxford BioDynamics PLC is a global biotechnology company advancing personalized healthcare by developing and commercializing precision medicine tests for life-changing diseases. The company's core technology is the proprietary EpiSwitch® platform, which analyzes 3D genome regulation to discover and develop novel epigenetic biomarkers. Its primary products include the EpiSwitch® PSE, a blood test that detects the likelihood of prostate cancer with high accuracy to reduce unnecessary biopsies, and the EpiSwitch® CiRT, a test to predict a patient's therapeutic response to Immune Checkpoint Inhibitor cancer therapies. Oxford BioDynamics focuses on translating genomic data into clinically actionable insights to improve diagnosis and treatment guidance.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2025-09-10 08:00 |
Major Shareholding Notification
Holding(s) in Company
|
English | 22.1 KB | ||
| 2025-09-04 11:00 |
Regulatory News Service
Study confirms clinical utility of EpiSwitch CiRT
|
English | 19.2 KB | ||
| 2025-08-13 08:00 |
Regulatory News Service
Collaboration with Google Cloud
|
English | 12.0 KB | ||
| 2025-07-18 16:11 |
Major Shareholding Notification
Holding(s) in Company
|
English | 21.9 KB | ||
| 2025-07-17 08:01 |
Report Publication Announcement
GenomeWeb to host joint Agilent/OBD presentation
|
English | 18.3 KB | ||
| 2025-07-17 08:00 |
Major Shareholding Notification
Holding(s) in Company
|
English | 23.3 KB | ||
| 2025-07-15 18:20 |
Major Shareholding Notification
Holding(s) in Company
|
English | 23.2 KB | ||
| 2025-07-15 08:00 |
Regulatory News Service
Pfizer study on EpiSwitch biomarkers
|
English | 19.7 KB | ||
| 2025-07-01 16:00 |
Major Shareholding Notification
Holding(s) in Company
|
English | 23.3 KB | ||
| 2025-06-30 08:00 |
Earnings Release
Interim Results
|
English | 706.2 KB | ||
| 2025-06-27 14:30 |
Major Shareholding Notification
Holding(s) in Company
|
English | 23.3 KB | ||
| 2025-03-28 11:35 |
Post-Annual General Meeting Information
Result of AGM
|
English | 12.3 KB | ||
| 2025-03-17 08:00 |
Board/Management Information
Board Changes
|
English | 18.2 KB | ||
| 2025-03-14 18:25 |
Major Shareholding Notification
Holding(s) in Company
|
English | 23.2 KB | ||
| 2025-03-13 08:00 |
Regulatory News Service
Expansion of OBD/Bupa UK insurance partnership
|
English | 26.1 KB |
Automate Your Workflow. Get a real-time feed of all OXFORD BIODYNAMICS PLC filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
No Financial Data Available
Standardized financial statements for the selected period are not yet available.
Need More History? Access decades of standardized financials for OXFORD BIODYNAMICS PLC via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
